Grifols, S.A. (NASDAQ:GRFS – Get Free Report) saw a large decrease in short interest in the month of August. As of August 31st, there was short interest totalling 5,530,000 shares, a decrease of 9.5% from the August 15th total of 6,110,000 shares. Based on an average daily trading volume, of 1,740,000 shares, the short-interest ratio is presently 3.2 days. Currently, 2.2% of the shares of the stock are short sold.
Grifols Price Performance
Grifols stock traded down $0.16 during mid-day trading on Wednesday, hitting $8.74. The stock had a trading volume of 560,932 shares, compared to its average volume of 2,124,579. The company has a current ratio of 1.68, a quick ratio of 0.80 and a debt-to-equity ratio of 1.06. The firm’s 50 day moving average is $8.15 and its 200 day moving average is $7.29. Grifols has a one year low of $5.30 and a one year high of $12.15.
Grifols (NASDAQ:GRFS – Get Free Report) last issued its earnings results on Tuesday, July 30th. The biotechnology company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.21). The firm had revenue of $1.96 billion during the quarter. Grifols had a return on equity of 1.73% and a net margin of 0.90%. On average, sell-side analysts expect that Grifols will post 0.79 EPS for the current fiscal year.
Institutional Investors Weigh In On Grifols
About Grifols
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.
Featured Articles
- Five stocks we like better than Grifols
- Profitably Trade Stocks at 52-Week Highs
- How Much Can You Make in Stocks in One Month?
- What Is WallStreetBets and What Stocks Are They Targeting?
- This Is the Top Large-Cap Stock Insiders Are Buying
- Conference Calls and Individual Investors
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.